EU demand for plant extracts continues to grow

In 2010, the main export markets of plant extracts in China are still Japan and the United States, with the export volume exceeding 100 million US dollars, but the export growth rate has been weak, less than 10% What's striking is the EU market Last year, China's export of plant extract products to the EU market was US $182 million, a year-on-year increase of 49.15%, far higher than the average growth of China's export of plant extract products, especially in the EU countries dominated by Germany, France and the UK In 2010, China's import of plant extract products increased by more than 60% Most of the products are used for plant medicine and food supplements According to the statistics of China's customs, the import and export trade of Chinese extract products to the EU continued to grow from 2001 to 2009 As of 2009, the total import and export volume of China's extract products to the EU has reached 138 million US dollars, a year-on-year growth of 7.4%; among them, the export volume is 120 million US dollars, a year-on-year growth of 2.5%, and the annual growth rate of China's extract products to the EU from 2001 to 2009 is 10.9% As one of the largest market, production and R & D centers of cosmetics and health food in the world, Europe has a long history of traditional herbal medicine application Modern plant medicine started early, developed rapidly, and has a high market share It is the largest plant medicine market in the world In 2005, its scale has reached 9 billion US dollars, accounting for 34.5% of the global plant medicine market, with an average annual growth rate of 6% - 7% According to statistics, more than 60% of Europeans have used traditional plant medicine In Europe, plant extracts are widely used as raw materials of plant medicine products At present, there are three types of plant extract products with the fastest growth in the EU market: first, health care products with preventive effect, such as garlic and ginseng; second, old products recognized by medical institutions, such as those for insomnia and neurosis; third, old products with new therapeutic effect, such as evening primrose oil and Ginkgo biloba preparation, have been found European governments and academic circles all hold a positive attitude towards plant extracts, and the research on plant drugs and traditional drugs is continuously strengthened Plant drugs represented by Ginkgo preparations are widely welcomed Plant extract, as a semi-finished product in the production process of plant medicine products, has certain substitutability In the case that the quality of the extract or the manufacturer does not meet the standard or is difficult to meet the standard, the manufacturer of botanical drugs usually adopts the way of turning to the imported medicine to extract by itself to ensure the quality of the product and reduce the cost The most typical example of this is the export of Ginkgo biloba extract At present, the main standards of Ginkgo biloba extract in the world are epg246, G328 and G320 Because the quality of Ginkgo biloba extract produced by many enterprises in China is not stable enough or can not meet the standard requirements, and most enterprises fail to pass the EU GMP certification and European cos certification (that is, the raw materials of products meet the European pharmacopoeia standard certification), their products can not be used as pharmaceutical raw materials within the EU The major pharmaceutical enterprises of Ginkgo biloba extract in France and Germany have turned to import a large number of Ginkgo biloba leaves for self extraction In the EU, the production of botanical drugs has certain local characteristics, and the extract products exported by Chinese enterprises may not be the varieties needed by EU botanical drug enterprises; or some plant resources in China are just the varieties needed by European enterprises, but Chinese enterprises or due to technical reasons have not yet developed them Therefore, China's extractive enterprises should keep close contact with European Union's local botanical drug manufacturers or agents, obtain market information in time, and make targeted and focused selection of extractive varieties For the dominant plant resources in China, cooperative development can be considered, and the market can be jointly developed in various ways In addition, as the raw materials of herbal preparations, the product packaging and label design, market development and sales network can be established by developers familiar with the local market, which can also greatly reduce the difficulty of market operation.